News Focus
News Focus
icon url

Investor2014

05/06/22 4:57 PM

#359529 RE: boi568 #359528

Cons are one open label AD P2 trial with really small posthoc analysis subgroups and a theoretical correlation between a PDD and AD scoring system.

From that we can infer some numbers none of which are terrible reliable despite being encouraging.

We really won’t know with any certainty beyond a coin toss until the fat lady sings.